We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Neovasc (NVCN) Releases Update on Reducer and Tiara Products
Read MoreHide Full Article
Neovasc Inc. recently announced that the company is bullish on its flagship products — Reducer and Tiara — for the treatment of angina at the SVB Leerink 9th Annual Global Healthcare Conference.
For investors’ notice, Neovasc’s Reducer is an effective, percutaneous treatment for refractory angina. The product recently received a CE mark and the company is on track to submit a pre-market approval to the FDA by 2020-end.
Meanwhile, Tara is a transcatheter device designed to treat mitral regurgitation. Neovasc looks forward to obtain a CE Mark for Tiara in Europe.
More on the Update
Per management, the market dynamics for Reducer have been changing favorably, which is expected to ramp up sales for the product. Moreover, Neovasc has established partnerships in Europe and has been making significant progress with respect to the sale of Reducer in Germany. Thus, the company expects to see double-digit growth from Reducer in the quarters ahead.
Additionally, clinical studies on the Tiara I and II are likely to help the device obtain a CE Mark by 2021.
Notably, the company has been investing in the successful commercialization of these devices. It is encouraging to note that Neovasc currently has a cash of $14.1 million in hand, which is expected to last till August.
Market Prospects
A study by Reports and Data suggests that the global cardiovascular devices market is expected to reach a worth of $69.08 billion by 2026, at a CAGR of 6.8%.
Hence, the latest development has been a well-timed one for Neovasc.
However, the company faces stringent competition from other MedTech bigwigs which specialize in cardiovascular devices. These include ABIOMED , Boston Scientific (BSX - Free Report) and Abbott Laboratories (ABT - Free Report) .
ABIOMED’s Impella, Boston Scientific’s Accolade and Abbott’s Amplazter deserve a mention in this regard.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Neovasc (NVCN) Releases Update on Reducer and Tiara Products
Neovasc Inc. recently announced that the company is bullish on its flagship products — Reducer and Tiara — for the treatment of angina at the SVB Leerink 9th Annual Global Healthcare Conference.
For investors’ notice, Neovasc’s Reducer is an effective, percutaneous treatment for refractory angina. The product recently received a CE mark and the company is on track to submit a pre-market approval to the FDA by 2020-end.
Meanwhile, Tara is a transcatheter device designed to treat mitral regurgitation. Neovasc looks forward to obtain a CE Mark for Tiara in Europe.
More on the Update
Per management, the market dynamics for Reducer have been changing favorably, which is expected to ramp up sales for the product. Moreover, Neovasc has established partnerships in Europe and has been making significant progress with respect to the sale of Reducer in Germany. Thus, the company expects to see double-digit growth from Reducer in the quarters ahead.
Additionally, clinical studies on the Tiara I and II are likely to help the device obtain a CE Mark by 2021.
Notably, the company has been investing in the successful commercialization of these devices.
It is encouraging to note that Neovasc currently has a cash of $14.1 million in hand, which is expected to last till August.
Market Prospects
A study by Reports and Data suggests that the global cardiovascular devices market is expected to reach a worth of $69.08 billion by 2026, at a CAGR of 6.8%.
Hence, the latest development has been a well-timed one for Neovasc.
However, the company faces stringent competition from other MedTech bigwigs which specialize in cardiovascular devices. These include ABIOMED , Boston Scientific (BSX - Free Report) and Abbott Laboratories (ABT - Free Report) .
ABIOMED’s Impella, Boston Scientific’s Accolade and Abbott’s Amplazter deserve a mention in this regard.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>